In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

International Journal of Antimicrobial Agents

Volumn 46, Issue 5, 2015, Pages 502-510

  Tato, Marta ^a,b   García Castillo, María ^a,b   Bofarull, Ana Moreno ^a,c   Cantón, Rafael ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Antimicrobial resistance; Ceftolozane tazobactam; Gram negative; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SERRATIA MARCESCENS; WILD TYPE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; SPAIN; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPAIN;

EID: 84947035840     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.07.004     Document Type: Article

References (30)

1. D.M. Sievert, P. Ricks, J.R. Edwards, A. Schneider, J. Patel, A. Srinivasan, and et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 Infect Control Hosp Epidemiol 34 2013 1 14
2. M. Sartelli, F. Catena, L. Ansaloni, A. Leppaniemi, K. Taviloglu, H. van Goor, and et al. Complicated intra-abdominal infections in Europe: preliminary data from the first three months of the CIAO Study World J Emerg Surg 7 2012 15
3. H.S. Sader, D.J. Farrell, R.K. Flamm, and R.N. Jones Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012 Int J Antimicrob Agents 43 2014 328 334
4. M. Marcos, A. Soriano, A. Iñurrieta, J.A. Martínez, A. Romero, N. Cobos, and et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens J Antimicrob Chemother 66 2011 2119 2125
5. A.Y. Peleg, and D.C. Hooper Hospital-acquired infections due to Gram-negative bacteria N Engl J Med 362 2010 1804 1813
6. E.J. Joo, C.I. Kang, Y.E. Ha, S.Y. Park, S.J. Kang, Y.M. Wi, and et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection Infection 39 2011 309 318
7. S. Micek, M.T. Johnson, R. Reichley, and M.H. Kollef An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with Gram-negative sepsis BMC Infect Dis 12 2012 56
8. P.D. Mauldin, C.D. Salgado, I.S. Hansen, D.T. Durup, and J.A. Bosso Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria Antimicrob Agents Chemother 54 2010 109 115
9. F. Wagenlehner, O. Umeh, J. Huntington, D. Cloutier, I. Friedland, J. Steenbergen, and et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in hospitalized adults: results from the phase 3 ASPECT-cUTI trial 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 May 2014; Barcelona, Spain 2014 ESCMID Basel, Switzerland [poster eP449]
10. C. Eckmann, E. Hershberger, B. Miller, M. Wooley, I. Friedland, J. Steenbergen, and et al. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalized adults: results from the phase 3 ASPECT-cIAI trial 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 May 2014; Barcelona, Spain 2014 ESCMID Basel, Switzerland [poster P0266a]
11. G.G. Zhanel, P. Chung, H. Adam, S. Zelenitsky, A. Denisuik, F. Schweizer, and et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli Drugs 74 2014 31 51
12. H.S. Sader, P.R. Rhomberg, D.J. Farrell, and R.N. Jones Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes Antimicrob Agents Chemother 55 2011 2390 2394
13. D.J. Farrell, R.K. Flamm, H.S. Sader, and R.N. Jones Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012) Antimicrob Agents Chemother 57 2013 6305 6310
14. E. Titelman, I.M. Karlsson, Y. Ge, and C.G. Giske In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae Diagn Microbiol Infect Dis 70 2011 137 141
15. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2012. ECDC. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf [accessed 28.07.15].
16. International Organization for Standardization. ISO 20776-1:2006. Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. http://www.iso.org/iso/catalogue-detail.htm?csnumber=41630 [accessed 23.12.14].
17. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014 2014 EUCAST http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf [accessed 28.07.15]
18. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23 2013 CLSI Wayne, PA
19. Cubist Pharmaceuticals Prescribing information for ZERBAXA™ 2015 Cubist Pharmaceuticals Lexington, MA http://www.zerbaxa.com/pdf/PrescribingInformation.pdf [accessed 01.06.15]
20. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - ninth edition. Document M07-A9 2012 CLSI Wayne, PA
21. European Committee on Antimicrobial Susceptibility Testing EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0, December 2013 2013 EUCAST http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Resistance-mechanisms/EUCAST-detection-of-resistance-mechanisms-v1.0-20131211.pdf [accessed 28.07.15]
22. V. Jarlier, M.H. Nicolas, G. Fournier, and A. Philippon Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns Rev Infect Dis 10 1988 867 878
23. P. Nordmann, L. Poirel, and L. Dortet Rapid detection of carbapenemase-producing Enterobacteriaceae Emerg Infect Dis 18 2012 1503 1507
24. K. van Dijk, G.M. Voets, J. Scharringa, S. Voskuil, A.C. Fluit, W.C. Rottier, and et al. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin Clin Microbiol Infect 20 2014 345 349
25. D.M. Livermore β-Lactamases in laboratory and clinical resistance Clin Microbiol Rev 8 1995 557 584
26. J. Oteo, E. Lázaro, F.J. de Abajo, F. Baquero, J. Campos Spanish members of EARSS Antimicrobial-resistant invasive Escherichia coli Spain. Emerg Infect Dis 11 2005 546 553
27. N. van de Sande-Bruinsma, H. Grundmann, D. Verloo, E. Tiemersma, J. Monen, H. Goossens, and et al. Antimicrobial drug use and resistance in Europe Emerg Infect Dis 14 2008 1722 1730
28. D.M. Livermore, S. Mushtaq, and Y. Ge Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae J Antimicrob Chemother 65 2010 1972 1974
29. S. Takeda, T. Nakai, Y. Wakai, F. Ikeda, and K. Hatano In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa Antimicrob Agents Chemother 51 2007 826 830
30. A. Walkty, J.A. Karlowsky, H. Adam, M. Baxter, P. Lagace-Wiens, D.J. Hoban, and et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012 Antimicrob Agents Chemother 57 2013 5707 5709